Patients with Gaucher disease (GD) have an increased risk of monoclonal gammopathies for which antigenic targets might play a role in their pathogenesis. Here we report the identification of saposin C (sapC) as high-titre (1:1 000 000) target structure of 7/16 GD-associated paraproteins. AntisapC immunoglobulin (Ig) showed identity with the paraprotein Ig type and subclass in each patient that showed anti-sapC immunoreactivity. Absorption and depletion studies completely removed the paraprotein from the sera of GD patients. No immunoreactivity against sapC was detected in healthy donors and in other plasma cell dyscrasias, demonstrating that anti-sapC reactivity is highly restricted to GD. Several uncharacterized forms of post-translational modified sapC were detected but their role in the pathogenesis is not clear. We confirm the frequent presence of low-titre (1:250) anti-lysolipid reactivities in the sera of GD patients but we could show that this immunoreactivity is not mediated by the paraprotein and is not restricted to GD patients.
Gaucher disease (GD; Online Mendelian Inheritance in Man reference 230800) is a rare lysosomal storage disorder in which the lysosomal enzyme glucocerebrosidase (GBA1, also termed GBA) is deficient. Clinically, the disease manifests with hepatosplenomegaly, cytopenia and bone disease due to infiltration of organs and bone marrow with Gaucher cells: lipid engorged storage macrophages (Grabowski, 2008) . A late complication of the disease is the occurrence of mutliple myeloma (MM), which is often fatal (Arends et al, 2013) . The results of several studies (Greenberg et al, 2012) have suggested a causal relationship with chronic antigenic stimulation in monoclonal gammopathy of uncertain significance (MGUS)/MM in general, but only few antigenic targets/stimuli have been reported that hold scrutiny. Recently, it was reported that the clonal immunoglobulins (Igs) from 85% of patients with GD were associated with, and 31% with sporadic MGUS/MM react with, lysolipids, specifically lysoglucosylceramide (glucosylsphingosine, LGL1) and lysophosphatidylcholine (LPC) (Nair et al, 2016) . The reported low anti-lysolipid titres (1:250) raised doubts about whether the observed reactions were mediated by the clonal Ig (i.e. the paraprotein), because paraprotein-mediated reactions against their specific targets are always observed at dilutions >1:10 6 up to 1:10 10 (Preuss et al, 2007 (Preuss et al, , 2011 (Preuss et al, , 2015 Grass et al, 2009) . By analysing GD sera with high-titre paratarg-7-specific paraprotein and low-titre LGL1 immunoreactivity we showed, by Ig-subtype analysis, that LGL immunoreactivity Ig (sub)class differed from paraprotein-mediated immunoreactivity ( Figure S1 ). This result strengthened our doubts and prompted us to start a new and systematic screening for GD-associated paraprotein target structures without any pretentions.
Methods

Patients and controls
Peripheral blood samples from patients and healthy controls were collected after obtaining written informed consent. Samples from GD patients were obtained from the SPHINX biobank (www.a mcbiobank.nl), in accordance with Dutch ethics guidelines. The study had been approved by the competent local authority, the ethics committee of the € Arztekammer des Saarlandes. Screening of GD-associated paraproteins on high density human protein macroarrays
High density protein arrays of the protein expression set of the hEx1 library, consisting of 37 830 independent clones derived from a human fetal brain cDNA expression library (Bussow et al, 1998 ) (Source BioScience plc, Nottingham, UK and available from engine GmbH, Hennigsdorf, Germany) were screened as described ) with a pool of 16 paraprotein-containing GD sera at a dilution of 1:10 6 . The signals were verified using single sera at high dilution.
Identification of the paraprotein-binding prosaposin (PSAP) epitope
The PSAP clone, originally identified on the membrane (NM_001042465), was obtained from Source Bioscience. Using this clone as the template, Saposin B, C and D and partial fragments of Saposin C (sapC) were amplified by means of specific primers, cloned and recombinantly expressed as FLAG-tagged proteins in HEK293 cells. Total cell extracts were prepared and coated indirectly on Nunc maxisorb plates using anti-FLAG mAb (Sigma, Munich, Germany). Enzymelinked immunosorbent assays (ELISAs) were performed according to standard protocols with goat anti-human IgA, anti-IgG, anti-IgM and anti-human Fc. Anti-human Ig, IgG, IgA, IgM, Fc, k, j (DAKO, Copenhagen, Denmark) and IgG subclass-specific antisera (The Binding Site, Birmingham, UK) were used to determine the Ig subclass of the antibodies.
ELISA
SapC-specific ELISA was performed according to standard protocols using recombinantly expressed FLAG-tagged sapC as described above.
LGL1-specific ELISA was performed as described by Nair et al (2016) .
Absorption studies
Affi-Gel Hz hydrazide gel-activated support (Biorad, Munich, Germany) was used to immobilize anti-FLAG antibody (Sigma) according to the manufacturer's protocol. Recombinant FLAG-tagged sapC protein was incubated with this matrix, washed and used for depletion of sapC-specific immunoreactivity from sera. Bound sapC antibodies were eluted with 0Á2 mol/l glycine pH 3. For depletion of LGL1 immunoreactivity from sera, sphingosine beads (Echelon Biosciences Inc., Salt Lake City, USA) were used and eluted in a modification of the manufacturer's protocol by 0Á2 mol/l glycine pH3.
Isoelectric focusing (IEF)
Isoelectric focusing was performed as described .
Western blot
Western blots were performed as previously described ).
Antigen-specific SPEP-Immunoblots
Polyvinylidene difluoride (PVDF) membranes that were saturated with the antigen (LGL1; Avanti Polar Lipids Inc., Alabaster, Alabama, USA) or in-house recombinant sapC were prepared by incubation with 100 lg/ml antigen in 0Á5 mol/l sodium bicarbonate, washed with phosphate buffered saline (PBS)/0Á05% Tween 20, and blocked with 1% bovine serum albumin. Gels for serum protein electrophoresis were blotted onto those membranes by semi-dry blotting and blocked with 10% dry milk powder in PBS/Tween 20. The membrane was incubated with appropriate horseradish peroxidase (HRP)-conjugated secondary antibody -washed with Trisbuffered Tween, followed by enhanced chemiluminescence development.
Serum electrophoresis
Serum electrophoresis was performed as done for routine diagnosis using a capillary electrophoresis (CE) instrument (Sebia GmbH, Fulda, Germany).
Results
Serum samples from 21 GD patients, all found to have a paraprotein in their serum, were included in this study. The control group consisted of GD patients with no paraprotein in their sera as demonstrated by immunofixation and healthy blood donors.
Identification of SapC as predominant target of GD-associated paraproteins
Paraprotein-containing sera from 16 GD patients (6 IgA, 10 IgG) diluted 1:10 6 were screened for reactivity with the recombinant proteins spotted on the macroarray. In addition to some non-specific signals or those that are caused by the secondary system (Igs), a highly specific signal was detected ( Figure S2 ) which was represented by a partial PSAP clone (Prosaposine, NM_001042465, coding for as139-Stop 524 ). No other specific signals were detected on unmodified membranes or on membranes modified to represent secondary modified proteins [sumoylated (Preuss et al, 2015) , citrullinated, nitrosylated, acetylated, ubiquitinylated (unpublished methods)]. Verification and assignment of the immunoreactivity to individual patients reveraled that 7 of the 16 sera used showed immunoreactivity at a titre of 1:10 6 while the other 9 sera showed immunoreactivity at a titre of 1:100 maximum. In all these cases, anti-PSAP immunoreactivity was identical to the paraprotein Ig type or subtype. Recognition of PSAP was independent of the Ig type, Ig subtype or light chain of the paraprotein (Table I ). It is remarkable that 6 of the 7 sera showing high-titre immunoreactivity against PSAP also showed low-titre immunoreactivity (1:1000 max.) against LGL1, which was described as a GD-associated paraprotein target by Nair et al (2016) . Additionally, six of the 16 sera only showed low-titre immunoreactivity against LGL1 (1:1000 max.). Additional experiments showed that no immunoreactivity against PSAP was detected (titre 1:100) in healthy donors (n = 92), sera derived from patients with sporadic MM/ MGUS (n = 92), breast cancer (n = 48) and acute leukaemia (n = 48), as well as 140 patients with various autoimmune diseases ( Table SI) , demonstrating that anti-PSAP reactivity is highly restricted to patients with GD.
Saposin C in Gaucher Disease
PSAP is a highly conserved preproprotein that is proteolytically processed to generate four main cleavage products, saposins A, B, C and D (https://www.ncbi.nlm.nih.gov/gene/ 5660, Accessed 22 April 2017). Each domain of the precursor protein is approximately 80 amino acid residues long with nearly identical placement of cysteine residues and glycosylation sites.
Fine mapping of the epitope, which was recognized by the positive sera at a dilution of 1:10 6 , reveals that all sera specifically recognize PSAP aa355-393, which is identical to sapC aa42-80. With the exception of serum A5, which shows an additional low reactivity against sapA, none of the sera tested shows reactivity against saposin A, B or D (Fig 1A) . SapC was confirmed as an epitope by depletion of the paraprotein from immunopositive GD sera by using sapC affinity columns (representatively shown for serum A12 in Fig 1B) .
Immunoreactivity against SapC and LGL1 in GD sera
As summarized in Table I , 6/7 sera from patients with a GDassociated paraprotein showed immunoreactivity versus sapC and LGL1. We observed high-titre (1:10 6 ) immunoreactivity against sapC and low-titre (1:1000 max) immunoreactivity versus LGL1. In all these cases the LGL1 antibody Ig-type differs from the paraprotein Ig-type -which was identical with the type of the sapC antibody -indicating that LGL1 is not the paraprotein target structure in these cases. Selective isolation of both antibodies from the same serum clearly showed the simultaneous existence of these two antibodies in the same serum (representatively shown for serum A12 in Fig 2) . Analysis of the Ig and IgG subclasses of the clonal Igs (i.e. the paraproteins), the sapC reactive antibodies and the anti-lysolipid antibodies confirmed sapC as the paraprotein target structure and excluded the paraprotein-mediated nature of the anti-lysolipid reactivity (Table I) . 
GD, Gaucher disease; Ig, immunoglobulin; LGL1, glucosylsphingosine; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; PSAP, prosaposin.
We also showed that depletion of LGL1 immunoreactivity from such a serum by sphingosine beads did not completely remove the M-spike, as detected by serum electrophoresis, in contrast to its removal by depletion of sapC immunoreactivity by a sapC immunoaffinity column. (representatively shown for serum A12 in Fig 3) . Fig 1. (A) Saposin C contains the immunreactive epitope of PSAP. Prosaposin (PSAP) aa355-393 is recognized by 7/17 paraprotein-containing Gaucher disease (GD) sera while none of the sera tested showed immunoreactivity against other fragments of PSAP. Enzyme-linked immunosorbent assay was performed using recombinant PSAP fragments and sera diluted 1:10 6 . Black bar: GD sera 1-16 pooled; Grey bars: each column represents one of the 16 GD sera. Saposin A is PSAP aa60-142; saposin B is PSAB 196-274; saposin C is PSAP aa314-393 and saposin D is PSAP aa408-489. Numbering refers to NCBI GenPept NP_001035930.1 (prosaposin isoform b preproprotein). (B) Depletion of Saposin C immunoreactivity from serum of GD patient A12. The serum was depleted by means of a saposin C immunoaffinity column. Analysis of the serum before and after depletion was undertaken by serum electrophoresis and Western blotting using anti-human-IgG3. The depletion process removed the M-spike from the serum; saposin C immunoglobulin was retained on the column and, after elution, detected in the eluate of the column. S, sample; SD, sample depleted; E, eluate from sapC column.
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SapC is post-translationally modified in GD patients
SapC is one of four homologous proteins derived from sequential cleavage of the saposin precursor protein PSAP, and it has been reported to be present in body fluids (Hiraiwa et al, 1993; Chang et al, 2000) . In human blood, leucocytes contain mainly saposin while plasma mainly contains the precursor forms (Sano et al, 1989) . It is an essential activator for GBA1, the enzyme deficient in GD. SapC deficiency due to mutations in PSAP results in a Gaucher-like phenotype, despite normal in vitro GBA1 activity (Motta et al, 2014) . SapC comprises 80 amino acid residues, has a single N-glycosylation site and a structure characterized by five a-helices that is stabilized by six cysteine residues forming three intramolecular disulfide bridges and making the protein stable (O'Brien & Kishimoto, 1991; Vaccaro et al, 1995; de Alba et al, 1999) . Any substitution or deletion of one cysteine residue was predicted to break one of the three disulphide bridges leading to instability, misfunction and degradation of the protein. SapC deficiency caused by degraded mutant proteins has also been described (Motta et al, 2014) .
The high-titre immunoreactivity against sapC in GD patients prompted us to compare PSAP/sapC proteins derived from these patients with those from GD patients having an associated paraprotein with unknown specificity and from healthy donors. Sodium dodecyl sulphate polyacrylamide gel electrophoresis analysis showed no differences while IEF followed by immunodetection with an anti-SapC antibody clearly showed different banding of PSAP/sapC proteins (Fig 4) . While immunopositive bands in the samples derived from healthy donors (HD1, HD2) and in those derived from a GD patient with associated paraprotein of unknown specificity (GD A10) showed identical migration, PSAP/sapC derived from GD patients having a sapC antibodies from serum A12. Serum A12, which was immunoreactive against saposin C (sapC) and glucosylsphingosine (LGL1) was successively depleted from the first sapC immunoreactivity by means of a sapC immunoaffinity column followed by the second depletion of LGL1 immunoreactivity by sphingobeads. Both columns were washed and eluted with 0Á2 mol/ l glycine pH3. Analysis was performed by specific Enzyme-linked immunosorbent assay and Western blotting using anti-IgG3 (detection of sapC antibody) or anti-IgG1 (detection of LGL1 antibody). For isolation procedure and labelling see scheme above. E, depleted sample FT, flow through; S, sample; W, wash. specific paraprotein showed modified migration as detected by shifted and additional bands. This behaviour indicated modified PSAP/sapC proteins in GD A1, A3 and A14 (Fig 4; Figure S3 ) whereby a general pattern is not recognizable for GD patients. Given that sapC mutations can lead to lysosomal lipid accumulation or sapC deficiency in GD patients (Vaccaro et al, 2010) further investigations are needed to characterize the observed modifications in detail.
Discussion
We identified saposin C (sapC) as predominant high-titred (1:1 000 000) antigen in the sera of patients with GD. Analysis of the Ig and IgG subclasses of the clonal Igs (i.e. the paraproteins) and the anti-lysolipid antibodies, together with our absorption and depletion studies, confirmed SapC as the paraprotein target structure and excluded the paraproteinmediated nature of the anti-lysolipid reactivity.
SapC is an essential activator for GBA1, the enzyme deficient in GD (Tamargo et al, 2012) . In contrast to anti-lysolipid reactivities that were found not only in patients with GD, but also in a considerable proportion of patients with autoimmune diseases, we detected antibodies against sapC exclusively in patients with GD-associated MGUS/MM, but not in patients with a wide spectrum of other malignant or autoimmune diseases, demonstrating that autoimmunity against sapC is a highly specific phenomenon in GDassociated MGUS/MM. The reason for this remains unclear; several forms of post-translationally modified sapC variants were detected in sera from GD patients although no general pattern could be recognized. Given that sapC is not mutated in the majority of GD patients and our 16 patients had a confirmed mutation in GBA1, we did not detect antibodies against GBA1 either in our 16 patients with GD-associated MGUS/MM or in 10 other GD patients without a myelodyscrasia (data not shown). However, as an activator of GBA1, sapC has to bind to and form (at least temporary) complexes with the mutated GBA1 in GD, and it is conceivable that these complexes are autoimmunogenic, with the sapC within these complexes evolving as the target structure of the autoimmune response. Such a chronic autoantigenic stimulation by the mutated GBA1/sapC complex might eventually While we did confirm the reported prevalence of antilysolipid reactivities in the sera from patients with GD-associated and sporadic MGUS/MM, anti-lysolipid reactivities were also found in a significant proportion of patients with various autoimmune diseases (in addition to a small percentage of healthy controls and patients with other malignant diseases). The prevalence of anti-lysolipid reactivities in these patients is intriguing. It might mirror an increased B-cell activation and proliferation due to an increased release of cytokines, leading to polyclonal and monoclonal B-cell proliferation (Linari & Castaman, 2016 ) and a general predisposition towards autoimmunity.
Rather than lysolipids, sapC is the predominant antigen of the paraproteins from patients with GD-associated MGUS/ MM, suggesting that sapC is involved in the origin of a considerable proportion of GD-associated MGUS/MM. Our finding that one of the GD-associated paraproteins was directed against paratarg-7 indicates that other autoantigens could also be involved in the pathogenesis of GD-associated MGUS/MM. Given that hyperphosphorylated paratarg-7, which is inherited in a dominant fashion (and obviously independent of mutations of GBA1) is a strong risk factor for MGUS/MM in general, it might have forestalled or overridden the autoantigenic stimulus of the mutated GBA1/sapC complex in the affected patient. Nevertheless, that fact that nearly half of the GD-associated paraproteins were directed against sapC suggests that this molecule exerts the most consistent chronic antigenic stimulation in a population of GD patients that eventually results in the evolution of a malignant clone of plasma cells. Further studies need to identify the conditions (e.g. certain human leucocyte antigen haplotypes that are able to recognize and present the autostimulatory peptides of sapC) and other risk factors that determine whether a GD patient will eventually develop an MGUS/MM with a sapC-specific paraprotein.
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